Dose reductions of other antidiabetic medications may be needed, and appropriate ophthalmological monitoring is advised due to potential diabetic retinopathy changes
Obesity pharmacotherapy, such as GLP-1 receptor agonists, is often necessary for long-term weight management, and stopping these medications frequently results in weight regain
They do not activate the GLP-1 receptor with the same potency, which means your expected dose effectively becomes a smaller dose
Currently undergoing late-stage clinical trials for the treatment of obesity and type 2 diabetes, CagriSema combines semaglutide with a dual amylin and calcitonin receptor agonist called cagrilintide
While trezepatide shows a slight edge in weight loss and potential cardiovascular benefits, the choice ultimately depends on individual patient needs
Other researchers found that patients taking GLP-1 drugs had a 33% higher rate of aspiration pneumonia following endoscopy